泰杜格卢提德治疗不耐治疗的严重肠道急性移植对宿主疾病 - - 一项多中心调查
Niklas Brehm1, Francesca Biavasco1, Johannes Clausen2
1Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bone marrow transplantation
|April 14, 2025
概括
类似于葡萄糖类-2 (GLP-2) 的模拟泰杜格卢提德在干细胞移植后作为耐火性肠急性移植对宿主疾病 (aGVHD) 的救援疗法具有前景. 这种治疗似乎是安全的,并且在一些患者中表现出活性,因此需要进一步调查.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 在异性造血细胞移植 (allo-HCT) 后,耐药性肠急性移植对宿主疾病 (aGVHD) 与高非复发性死亡率 (NRM) 有关.
- 临床前研究表明aGVHD可以减少肠道L细胞,降低葡萄糖类-2 (GLP-2) 水平,并且GLP-2的使用可以改善小鼠的GVHD严重程度.
研究的目的:
- 为了评估特杜格胺的安全性和有效性,GLP-2模拟物,作为一种救援疗法,用于患者的类固醇耐药肠道aGVHD.
主要方法:
- 一项回顾性多中心调查,涉及17名SR-肠道aGVHD患者,接受了teduglutide治疗.
- 评估治疗反应 (CR/PR),生存率,血清白蛋白水平和不良事件.
主要成果:
- 在64.7%的患者 (11/17) 中观察到完全响应 (CR) 或部分响应 (PR) 的最佳反应,其中41.2%的患者达到CR (7/17).
- 在28周的随访中位数,17名患者中有10人还活着.
- 大多数患者在开始治疗的两个月内显示出血清白蛋白水平的增加,无论临床反应如何;没有报告与泰杜格卢类相关的显著毒性.
结论:
- 泰杜格胺似乎是一个安全的选择,在患有耐火性肠道aGVHD的患者的一个子组中表现出活性.
- 通过未来的临床试验进行进一步的验证是必要的,以确认这些发现.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120